CRISPR cell therapy trial seeks to tame Tough-to-Treat blood cancer
Disease control
Recruiting now
This early-stage study is testing the safety and best dose of a new cell therapy called CB-011 for people with multiple myeloma that has come back or stopped responding to other treatments. The therapy uses CRISPR gene-editing technology to create 'off-the-shelf' immune cells des…
Phase: PHASE1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC